Project Grant R01HL174056
Award Date
8/10/24
Completion Date
5/31/28
Dollars Obligated
$2.3M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84132, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $812,403 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The grant supports a series of experiments to investigate the mechanisms by which cardiac stereotactic body radiation therapy (CSBRT) impacts the structural and electrophysiological changes associated with ventricular...
This $810,964 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports the development of a novel non-invasive 3D mapping technique to accurately identify the site of origin for ventricular tachycardia (VT) and premature ventricular complexes (PVCs) using 12-lead ECG data. The project aims to create a computerized method that can automatically locate the VT exit/PVC origin site in real-time,...
The federal Project Grant award R01HL171118, in the amount of $2,541,492.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research focused on understanding the underlying mechanisms driving pathological remodeling of Purkinje cells, which play a critical role in the ventricular conduction system and the development of arrhythmias in common acquired cardiomyopathies. The research,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $317,285 to Rithim Biologics Inc. to develop a novel gene therapy approach to prevent ventricular tachycardia (VT) following a myocardial infarction. The key products and services include: The project aims to finalize development of a gene painting catheter to enable targeted ventricular gene transfer, verify ventricular transgene...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $393,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to support a population-based computational approach for arrhythmia prediction and therapy. The project aims to discover effective antiarrhythmic drug therapies and optimal clinical markers for arrhythmia risk prediction by leveraging mathematical modeling, computer simulation, and dynamical...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $643,426 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Utah. The grant aims to determine how the leukotriene B4 receptor (LTB4R) signaling axis promotes ventricular arrhythmias and evaluate its potential as a therapeutic target for preventing fatal cardiac events in patients with type 2 diabetes mellitus (T2DM). The research will use optical, electrophysiology, genetic, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $323,230.00 to Sirona Medical Technologies, Inc. to develop a multi-channel, dual-energy source generator for their proprietary cardiac ablation catheter system. The goal is to create a customizable generator that can seamlessly switch between radiofrequency (RF) and pulsed field (PF) energy sources and precisely deliver the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,866,119 to The Johns Hopkins University to conduct research on using novel computational modeling ("digital twin") approaches to characterize the role of infiltrating adipose tissue versus scarring in promoting ventricular arrhythmias in patients with ischemic cardiomyopathy. The research will leverage advanced...
This $866,240 National Institutes of Health National Heart, Lung and Blood Institute project grant funds the development of an innovative ablation system for inoperable hypertrophic cardiomyopathy patients at the University of Texas at Arlington from September 1, 2022 to August 31, 2025. The university researchers aim to design a controllable, localized ablation method to replace alcohol ablation and its risks. They will develop a collagenase-coated, doxorubicin-loaded degradable nanoparticle...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $977,998.39 to conduct the "VENOUS ETHANOL ABLATION IN ISCHEMIC VENTRICULAR TACHYCARDIA- VELVET TRIAL". The research aims to evaluate the clinical efficacy and safety of using venous ethanol ablation in combination with radiofrequency (RF) ablation, compared to RF ablation alone, for treating ischemic ventricular...